Document is current
Any future updates will be listed below
-
Authors
Mackin, R. Scott
Rhodes, Emma
Kassel, Michelle
Kryza-Lacombe, Maria
Burns, Emily
Bickford, David
Morin, Ruth
Tosun, Duygu https://orcid.org/0000-0001-8644-7724
Landau, Susan
Butters, Meryl A. https://orcid.org/0000-0002-2563-817X
Aisen, Paul
Raman, Rema
Saykin, Andrew J. https://orcid.org/0000-0002-1376-8532
Toga, Arthur https://orcid.org/0000-0001-7902-3755
Koeppe, Robert
Jack, Clifford https://orcid.org/0000-0001-7916-622X
Weiner, Michael W.
Nelson, Craig
Insel, Philip S.
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH098062-05S1)
- License Information
-
More Information
Article History
Received: 27 October 2023
Revised: 31 May 2024
Accepted: 15 July 2024
First Online: 7 November 2024
Competing interests
: During the past 2 years, RSM has received research support from The National Institute of Mental Health, the National Institute of Aging, and Johnson and Johnson. During the past 2 years, CN has been an advisor or consultant to Biohaven, Clexio Biosciences Ltd., Johnson and Johnson, Novartis, and Otsuka, has received royalties from UpToDate, and research support from National Institute of Mental Health. RM, ER, DT, AT, RR, CJ, RK, MK, MKL, MAB, EB, and DB reported no biomedical financial interests or potential competing interests. SL serves on DSMBs for KeifeRX and the NIH IPAT study. She has received speaking honoraria from Eisai and IMPACT-AD and serves as a consultant for Vaccinex and the eSMARTER trial. She is on the JAMA Neurology editorial board and receives research funding and other support from NIH and the Alzheimer’s Association. AJS receives support from multiple NIH grants and has received support from Avid Radiopharmaceuticals, a subsidiary of Eli Lilly (in kind contribution of PET tracer precursor); Bayer Oncology (Scientific Advisory Board); Eisai (Scientific Advisory Board); Siemens Medical Solutions USA, Inc. (Dementia Advisory Board); NIH NHLBI (MESA Observational Study Monitoring Board); Springer-Nature Publishing (Editorial Office Support as Editor-in-Chief, Brain Imaging and Behavior). MWW has served on the Scientific Advisory Boards for Pfizer, BOLT International, Neurotrope Bioscience, Alzheon, Inc., Alzheimer’s Therapeutic Research Institute (ATRI), Eli Lilly, U. of Penn’s Neuroscience of Behavior Initiative, National Brain Research Centre (NBRC), India, Dolby Family Ventures, LP, and ADNI. PA has research grants from NIH, Lilly and Eisai, and consults with Merck, Roche, Genentech, Abbvie, Biogen, ImmunoBrain Checkpoint and Arrowhead. PSI consults with Roche and Merck.
: All participants provided written informed consent and all study procedures were approved by an Institutional Review Board.
